Abstract
ThyroidVol. 25, No. 4 Letter to the EditorAdrenal Reserve Following Treatment of Graves' Orbitopathy with Intravenous GlucocorticoidsZoe Giotaki, Athanasios Fountas, Theodora Tsirouki, Alexandra Bargiota, Stelios Tigas, and Agathocles TsatsoulisZoe GiotakiDepartment of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.Search for more papers by this author, Athanasios FountasDepartment of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.Search for more papers by this author, Theodora TsiroukiDepartment of Ophthalmology, University Hospital of Larisa, Larisa, Greece.Search for more papers by this author, Alexandra BargiotaDepartment of Endocrinology, University Hospital of Larisa, Larisa, Greece.Search for more papers by this author, Stelios TigasDepartment of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.Search for more papers by this author, and Agathocles TsatsoulisDepartment of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.Search for more papers by this authorPublished Online:1 Apr 2015https://doi.org/10.1089/thy.2014.0533AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Adrenal Reserve Following Treatment of Graves' Orbitopathy with Intravenous Glucocorticoids." Thyroid, 25(4), pp. 462–463FiguresReferencesRelatedDetailsCited byDrug safety in thyroid eye disease – a systematic review15 August 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 7Insuffisance corticotrope postcortisonothérapieGlucocorticoid induced adrenal insufficiency12 July 2021 | BMJ, Vol. 36What we have to know about corticosteroids use during Sars-Cov-2 infection28 August 2020 | Journal of Endocrinological Investigation, Vol. 44, No. 4Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice20 April 2021 | Diagnostics, Vol. 11, No. 4Functionally enhanced placenta-derived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves’ ophthalmopathy5 November 2020 | Stem Cell Research & Therapy, Vol. 11, No. 1Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate9 October 2020 | Journal of Clinical Medicine, Vol. 9, No. 10Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy4 January 2019 | Eye, Vol. 33, No. 2Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye DiseaseOphthalmic Plastic & Reconstructive Surgery, Vol. 34, No. 4SAdvances in treatment of active, moderate-to-severe Graves' ophthalmopathyThe Lancet Diabetes & Endocrinology, Vol. 5, No. 2 Volume 25Issue 4Apr 2015 InformationCopyright 2015, Mary Ann Liebert, Inc.To cite this article:Zoe Giotaki, Athanasios Fountas, Theodora Tsirouki, Alexandra Bargiota, Stelios Tigas, and Agathocles Tsatsoulis.Adrenal Reserve Following Treatment of Graves' Orbitopathy with Intravenous Glucocorticoids.Thyroid.Apr 2015.462-463.http://doi.org/10.1089/thy.2014.0533Published in Volume: 25 Issue 4: April 1, 2015Online Ahead of Print:February 12, 2015Online Ahead of Editing: January 20, 2015PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
